Treatment of Autoimmune Hemolytic Anemia with Immune Thrombocytopenia

Initial Treatment Approach

The European Society for Medical Oncology (ESMO) recommends initiating corticosteroids as first-line therapy for both Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP), with high-dose corticosteroids (prednisone 1-2 mg/kg/day or methylprednisolone 1g IV daily for 3 days), representing Level III evidence with Strength of Recommendation B 1, 2, 3
The initial treatment approach consists of corticosteroids for both conditions simultaneously, starting with high-dose corticosteroids: prednisone 1-2 mg/kg/day orally or methylprednisoline 1g IV daily for 3 days if severe presentation, according to the Annals of the Rheumatic Diseases 1, 2, 4
Monitoring of platelet counts weekly and hemoglobin levels during initial treatment is crucial, as per the Annals of the Rheumatic Diseases 4

For patients with stable Chronic Lymphocytic Leukemia (CLL) ("Simple Autoimmunity"), rituximab should be considered before splenectomy, as recommended by the Annals of Oncology 1, 2, 3
Rituximab is particularly effective for cold antibody AIHA, according to the Annals of Oncology 1
For ITP specifically, rituximab, immunosuppressors, and splenectomy are all viable options in refractory cases, as per the Annals of Oncology 1, 2

The American College of Hematology recommends immunosuppressive agents, such as azathioprine (150 mg/day), mycophenolate mofetil, or cyclosporine (2.5-3 mg/kg/day), can be added to corticosteroids for severe or refractory cases, according to the Annals of Oncology and the journal Blood 1, 4, 7
Intravenous immunoglobulin (IVIG) (1 g/kg over 1-2 days) may be considered in the acute phase for rapid platelet elevation, particularly if bleeding risk is high, as recommended by the Annals of the Rheumatic Diseases 4
Thrombopoietin receptor agonists (romiplostim, eltrombopag) have shown effectiveness in ITP related to CLL not responding to corticosteroids, according to the Annals of Oncology 1, 2, 8

Patients with anemia or thrombocytopenia due to immune mechanisms have better outcomes than those with cytopenias from bone marrow infiltration by CLL, as per the Annals of Oncology 1, 2, 3